Tokyo, Japan and Cambridge, UK, 29 May 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) notes that Neurocrine Biosciences, Inc. announced that it had presented new positive data from ...
Nxera Pharma (TSE:4565) is poised for a turnaround, with revenue forecast to grow 9.5% per year and earnings expected to surge by 53.44% annually. This would outpace the broader Japanese market’s ...
$600 million of 4.450% Notes due 2031 (the “2031 Notes”); $900 million of 5.200% Notes due 2035 (the “2035 Notes”); and $500 million of 5.950% Notes due 2055 (the “2055 Notes”). The Notes will be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback